Recent Updates — VTVT

The Board of Directors approved the Third Amended and Restated By-Laws on October 1, 2026. Key changes include requiring stockholder director nominees to provide evidence of compliance with Rule 14a-19 five business days before a meeting, adjusting voting standards for non-director matters to a majority of votes cast, and designating U.S. federal district courts as the exclusive forum for Securities Act claims. The company is a clinical-stage biopharmaceutical firm focused on developing treatments for rare diseases.

vTv Therapeutics Inc. reported financial results for the second quarter ended June 30, 2026, posting a net loss of $13.1 million, or $1.05 per basic and diluted share, compared to a $6.0 million loss in the prior year period. Cash and cash equivalents stood at $86.6 million as of June 30, 2026, down from $88.9 million at year-end 2025. The company expects to complete enrollment in its Phase 3 CATT1 trial evaluating cadisegliatin for type 1 diabetes by the third quarter of 2026 and plans to initiate a Phase 2a hybrid closed-loop trial before year-end. vTv Therapeutics is a late-stage biopharmaceutical company developing oral small molecule therapies, primarily focused on treating type 1 diabetes.